Imunon, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Imunon is a clinical-stage biotechnology company developing TheraPlas immunotherapies and PLACCINE nucleic acid vaccines. Its lead clinical candidate, IMNN-001, is in Phase II development for advanced ovarian cancer. Financial statements are unaudited.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Licensing revenue | $0 | $125,000 |
| Research and development expense | $2.62 million | $3.10 million |
| General and administrative expense | $3.06 million | $2.87 million |
| Total operating expenses | $5.68 million | $5.97 million |
| Loss from operations | $5.68 million | $5.84 million |
| Net loss | $5.59 million | $10.47 million |
| Basic and diluted loss per share | $0.68 | $1.82 |
| Net cash used in operating activities | $4.09 million | $7.98 million |
No meaningful operating margin is available because the company reported no Q1 2023 revenue. The smaller year-over-year net loss primarily reflects the prior-year $4.55 million charge related to issuing and redeeming convertible preferred stock, alongside higher investment income; it does not indicate operating profitability.
At March 31, cash and cash equivalents were $10.40 million, available-for-sale investments were $20.78 million, and accrued investment interest was $0.12 million. The company reported $6.0 million of restricted cash pledged as collateral for its SVB loan. Total current assets were $36.33 million, current liabilities $10.42 million, and working capital $25.91 million. The balance sheet showed approximately $6.08 million of notes payable, net of financing-related amounts.
Q1 investing activities provided $0.52 million and financing activities provided $2.47 million, principally from ATM equity sales. The company sold 1,660,608 shares through its at-the-market facility for net proceeds of approximately $2.47 million. On April 21, 2023, it repaid the SVB loan for $6.45 million, including principal, interest, and fees, using the released $6.0 million collateral account.
Material changes and operating developments
- R&D expense declined 15% year over year. Lower clinical and regulatory costs were partly offset by increased PLACCINE development and chemistry, manufacturing, and controls spending.
- G&A expense increased 7%, reflecting higher professional and legal fees, CEO succession-related compensation, and staffing costs; lower stock-based compensation partly offset the increases.
- Investment income rose to $253,000 from $12,000, attributed to higher returns on short-term investments. Loan interest expense also increased amid rising rates.
- Common shares outstanding increased from 7.44 million at year-end 2022 to 9.10 million at March 31, 2023, primarily reflecting equity financing.
- The company wrote off a $13.4 million IPR&D asset in Q4 2022; its stated fair value was zero at March 31, 2023. The earn-out milestone liability was also zero following a 2022 write-off.
Outlook, risks, and contingencies
- Management said available capital resources were expected to fund operations for 12 months from issuance of the financial statements. It cited $31.3 million in cash, cash equivalents, short-term investments, and interest receivable, plus approximately $1.8 million of planned future New Jersey NOL sales. The filing also reports $6.0 million in restricted cash, which was subsequently used in the SVB repayment.
- Management expects continuing operating losses and substantial funding needs. Additional equity or debt financing, partnerships, licensing, or NOL sales may be needed; financing may dilute shareholders or require concessions on program rights. If funds are insufficient, the company may delay, reduce, or terminate development activities.
- OVATION 2, a Phase I/II study of IMNN-001 in advanced ovarian cancer, completed enrollment of 110 patients; topline results were expected in the first half of 2024. A separate Phase 1/2 collaboration evaluating IMNN-001 with Avastin began enrollment in February 2023, with a planned 50 patients.
- For PLACCINE, management planned to select another pathogen target and hold an FDA pre-IND meeting during 2023 ahead of potential human testing of a SARS-CoV-2 seasonal booster vaccine. These are plans, not assured outcomes.
- Risks include clinical and regulatory uncertainty, patient enrollment, competition, intellectual property, financing availability, and potential dilution. The filing reported no material change to the risk factors in the 2022 Form 10-K.
- After quarter-end, the company settled the Curia arbitration for $583,500, including interest and legal fees. A securities class action was dismissed with leave to amend, but no amended complaint was filed by the deadline. Other shareholder litigation and a books-and-records matter remained unresolved; the company said loss likelihood and range could not be determined.
Important facts for investors to verify
- Reconcile the MD&A statement that Q1 2023 net loss was $5.3 million with the financial statements’ reported net loss of $5.591 million.
- Assess cash runway after the April 21 SVB payoff, including the distinction between unrestricted funds and the $6.0 million of formerly restricted collateral.
- Track OVATION 2 topline timing and results, and the enrollment and endpoints of the IMNN-001/Avastin study.
- Monitor financing needs, ATM usage, share-count dilution, and the timing and proceeds of planned New Jersey NOL sales.
- Confirm the status and financial consequences, if any, of the remaining legal proceedings.